First clinical experiences with the tetravalent live vaccine against dengue (Qdenga®) in travellers: a multicentric TravVacNet study in Germany
Journal of Travel Medicine · 2025
DOI: 10.1093/jtm/taaf004 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Travel Medicine, 2025. Verfasst von Clara Köpke und 19 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Microbiology and Hygiene, Saarland University, Homburg/Saar, Kirrberger Str. 100, 66421 Homburg, Germany. Hauptthemen laut MEDLINE: Dengue Vaccines, Dengue, Travel. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Background
A study was conducted to assess the safety and tolerability of the tetravalent live-attenuated dengue vaccine Qdenga®, which received marketing approval in Germany in 2022. The study evaluated vaccine-related reactions in a predominantly dengue-naïve population, highlighting the importance of post-marketing surveillance as an essential component of safety evaluation for newly licensed vaccines.
Methods
Following dengue vaccination, participants were recruited for an anonymous online questionnaire through the national ‘Trav VacNet’ network in Germany. The questionnaire focused on post-vaccination reactions up to 18 days after the first and second vaccination, as well as previous travel history and coadministration.
Results
The study included 1176 participants, with a median age of 39 years (IQR 28–56), 53.2% female (n = 625), 46.5% male (n = 547), and 0.3% non-binary participants (n = 4). After the first dose, 51% of the participants reported systemic reactions such as headache [40% (190/474)], weakness [40% (189/474)], and malaise [32% (154/474)], which were most pronounced between days 7 and 11 post vaccination. After the second dose, localized signs and symptoms such as pain at the injection site [22% (n = 55/250)] were more common. Fever was more common after the first dose [20% (96/474)] vs. 2% (6/250) after the second. Females reported significantly more reactions than males after both vaccinations (1st dose P = 0.0002; 2nd dose P = 0.0003). A total of 334 (28%) co-administrations were reported whereby assessing adverse events were reported in 47% (157/333) of participants, with the highest prevalence observed when combined with the Japanese encephalitis vaccine [56.8%, (42/74)]. Differences in age groups were observed, with a decrease in reactions in the elderly (≥65 years).
Conclusions
Vaccine-related reactions were frequently reported, predominantly after the first dose in dengue-naïve participants. Coadministration was a common strategy without significantly increasing side effects. The study provides important insights into reactogenicity and may help improve vaccination strategies in dengue-naïve populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Microbiology and Hygiene, Saarland University, Homburg/Saar, Kirrberger Str. 100, 66421 Homburg, Germany.
- LMU University Hospital Centre, Institute of Infectious Diseases and Tropical Medicine, Leopoldstraße 5, 80802 München, Germany.
- Medical Service, German Foreign Office, Regional Medical Office West Africa, Accra, No. 1, Drive North Ridge, Accra, Ghana.
- Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany.
- Division of Tropical Medicine, I. Department of Medicine, University Medical Center Hamburg-Eppendorf and Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Bernhard-Nocht-Straße 7…
- University of Tübingen, Institute of Tropical Medicine, Wilhelmstraße 2772074 Tübingen, Germany.
ORCID-Profile: Sören L Becker
Zitieren
APA
Köpke, C., Rothe, C., Zeder, A., Boecken, G., Feldt, T., Janke, C., Jordan, S., Köhler, C., Löbermann, M., Müller, A., Orth, H. M., Prüfer-Krämer, L. M., Schäfer, J., Slesak, G., Stich, A., Bélard, S., Thul, N., Becker, S. L., Schneitler, S., & TravVacNet-Group (2025). First clinical experiences with the tetravalent live vaccine against dengue (Qdenga®) in travellers: a multicentric TravVacNet study in Germany. Journal of Travel Medicine. https://doi.org/10.1093/jtm/taaf004
Vancouver
Köpke C, Rothe C, Zeder A, Boecken G, Feldt T, Janke C, et al. First clinical experiences with the tetravalent live vaccine against dengue (Qdenga®) in travellers: a multicentric TravVacNet study in Germany. Journal of Travel Medicine. 2025. doi:10.1093/jtm/taaf004
BibTeX
@article{Kpke2025,
author = {Köpke, Clara and Rothe, Camilla and Zeder, Andreas and Boecken, Gerhard and Feldt, Torsten and Janke, Christian and Jordan, Sabine and Köhler, Carsten and Löbermann, Micha and Müller, Andreas and Orth, Hans Martin and Prüfer-Krämer, Luise Marie and Schäfer, Johannes and Slesak, Günther and Stich, August and Bélard, Sabine and Thul, Nico and Becker, Sören L and Schneitler, Sophie and TravVacNet-Group, TravVacNet-Group},
title = {First clinical experiences with the tetravalent live vaccine against dengue (Qdenga®) in travellers: a multicentric TravVacNet study in Germany},
journal = {Journal of Travel Medicine},
year = {2025},
doi = {10.1093/jtm/taaf004}
}
EUVIMED